Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMOURA, Andrew D.
dc.contributor.authorCOSTA, Hernan H. M. da
dc.contributor.authorCORREA, Victor A.
dc.contributor.authorLIMA, Ana K. de S.
dc.contributor.authorLINDOSO, Jose A. L.
dc.contributor.authorGASPARI, Elizabeth De
dc.contributor.authorHONG, Marisa A.
dc.contributor.authorCUNHA-JUNIOR, Jair P.
dc.contributor.authorPRUDENCIO, Carlos R.
dc.date.accessioned2021-10-20T13:58:31Z
dc.date.available2021-10-20T13:58:31Z
dc.date.issued2021
dc.description.abstractSARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefined. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specificity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 8-14 and 15-21 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P < 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the first weeks of symptoms onset. Our findings constitute the effort to clarify IgG antibodies' kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more significant potential for life-threatening.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipNational Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [440812/2016-0]
dc.description.sponsorshipCoordination for the Improvement of Higher Education Personnel (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [88881.130804/2016-01]
dc.description.sponsorshipSao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [17/50333-7, 18/04202-0]
dc.description.sponsorshipMinistry of Health
dc.identifier.citationSCIENTIFIC REPORTS, v.11, n.1, article ID 17642, 13p, 2021
dc.identifier.doi10.1038/s41598-021-95045-z
dc.identifier.issn2045-2322
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/42243
dc.language.isoeng
dc.publisherNATURE PORTFOLIOeng
dc.relation.ispartofScientific Reports
dc.rightsopenAccesseng
dc.rights.holderCopyright NATURE PORTFOLIOeng
dc.subject.otheridentify pregnant-womeneng
dc.subject.otherantibody avidityeng
dc.subject.otherresponseseng
dc.subject.otherserumeng
dc.subject.othercoronaviruseng
dc.subject.otherprotectioneng
dc.subject.otherdiagnosiseng
dc.subject.otherpatternseng
dc.subject.otherimmunityeng
dc.subject.otherproteineng
dc.subject.wosMultidisciplinary Scienceseng
dc.titleAssessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patientseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalMOURA, Andrew D.:Adolfo Lutz Inst, Ctr Immunol, Sao Paulo, Brazil
hcfmusp.author.externalCOSTA, Hernan H. M. da:Adolfo Lutz Inst, Ctr Immunol, Sao Paulo, Brazil
hcfmusp.author.externalCORREA, Victor A.:Adolfo Lutz Inst, Ctr Immunol, Sao Paulo, Brazil
hcfmusp.author.externalLIMA, Ana K. de S.:Inst Infectol Emilio Ribas, Sao Paulo, Brazil
hcfmusp.author.externalGASPARI, Elizabeth De:Adolfo Lutz Inst, Ctr Immunol, Sao Paulo, Brazil
hcfmusp.author.externalHONG, Marisa A.:Adolfo Lutz Inst, Ctr Immunol, Sao Paulo, Brazil
hcfmusp.author.externalCUNHA-JUNIOR, Jair P.:Univ Fed Uberlandia, Dept Immunol, Lab Immunochem & Immunotechnol, Uberlandia, MG, Brazil
hcfmusp.author.externalPRUDENCIO, Carlos R.:Adolfo Lutz Inst, Ctr Immunol, Sao Paulo, Brazil
hcfmusp.citation.scopus40
hcfmusp.contributor.author-fmusphcJOSE ANGELO LAULETTA LINDOSO
hcfmusp.description.articlenumber17642
hcfmusp.description.issue1
hcfmusp.description.volume11
hcfmusp.origemWOS
hcfmusp.origem.pubmed34480056
hcfmusp.origem.scopus2-s2.0-85114601193
hcfmusp.origem.wosWOS:000695648400008
hcfmusp.publisher.cityBERLINeng
hcfmusp.publisher.countryGERMANYeng
hcfmusp.relation.referenceAmanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5eng
hcfmusp.relation.referenceAmanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007eng
hcfmusp.relation.referenceAndersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9eng
hcfmusp.relation.referenceAzkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364eng
hcfmusp.relation.referenceBachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024eng
hcfmusp.relation.referenceBauer G, 2021, INT J INFECT DIS, V106, P61, DOI 10.1016/j.ijid.2021.01.061eng
hcfmusp.relation.referenceBenner SE, 2020, J INFECT DIS, V222, P1974, DOI 10.1093/infdis/jiaa581eng
hcfmusp.relation.referenceBilich T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf7517eng
hcfmusp.relation.referenceBOPPANA SB, 1995, J INFECT DIS, V171, P1115, DOI 10.1093/infdis/171.5.1115eng
hcfmusp.relation.referenceCassaniti I, 2020, J MED VIROL, V92, P1724, DOI 10.1002/jmv.25800eng
hcfmusp.relation.referenceCastro R, 2020, BRAZ J INFECT DIS, V24, P180, DOI 10.1016/j.bjid.2020.04.003eng
hcfmusp.relation.referenceCavacini LA, 2003, AIDS RES HUM RETROV, V19, P785, DOI 10.1089/088922203769232584eng
hcfmusp.relation.referenceChan KH, 2007, CLIN VACCINE IMMUNOL, V14, P1433, DOI 10.1128/CVI.00056-07eng
hcfmusp.relation.referenceChen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7eng
hcfmusp.relation.referenceDe Azevedo M. S. P., 2021, JMIR PUBLIC HLTH SUReng
hcfmusp.relation.referenceDobano C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10195-zeng
hcfmusp.relation.referenceEisen HN, 2014, CANCER IMMUNOL RES, V2, P381, DOI 10.1158/2326-6066.CIR-14-0029eng
hcfmusp.relation.referenceEngin AB, 2020, ENVIRON TOXICOL PHAR, V78, DOI 10.1016/j.etap.2020.103411eng
hcfmusp.relation.referenceFelipe Rocha da Silva S, RES SQUARE, DOI [10.21203/rs.3.rs-402349/v2, DOI 10.21203/RS.3.RS-402349/V2]eng
hcfmusp.relation.referenceDelgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894eng
hcfmusp.relation.referenceFrasca D, 2017, CLIN EXP IMMUNOL, V187, P64, DOI 10.1111/cei.12824eng
hcfmusp.relation.referenceFrasca D, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-14eng
hcfmusp.relation.referenceGaspar EB., 2021, HUM VACC IMMUNOTHER, DOI [10.1080/21645515.2021.1920272, DOI 10.1080/21645515.2021.1920272]eng
hcfmusp.relation.referenceGreiner M, 1996, J IMMUNOL METHODS, V191, P93, DOI 10.1016/0022-1759(96)00013-0eng
hcfmusp.relation.referenceGuan W.-J., 2002, CLIN CHARACTERISTICSeng
hcfmusp.relation.referenceGuo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310eng
hcfmusp.relation.referenceHsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.xeng
hcfmusp.relation.referenceHuynh A., 2020, DEV SEROLOGICAL ASSA, V2009eng
hcfmusp.relation.referenceIwasaki A, 2020, NAT REV IMMUNOL, V20, P339, DOI 10.1038/s41577-020-0321-6eng
hcfmusp.relation.referenceJiang SB, 2020, TRENDS IMMUNOL, V41, P545, DOI 10.1016/j.it.2020.04.008eng
hcfmusp.relation.referenceJUNKER AK, 1994, J MED VIROL, V43, P119, DOI 10.1002/jmv.1890430204eng
hcfmusp.relation.referenceKaneko M, 2017, J INFECT CHEMOTHER, V23, P173, DOI 10.1016/j.jiac.2016.12.001eng
hcfmusp.relation.referenceKAWANO Y, 1994, J IMMUNOL, V153, P4948eng
hcfmusp.relation.referenceKellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439eng
hcfmusp.relation.referenceKhatri I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570018eng
hcfmusp.relation.referenceKontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568eng
hcfmusp.relation.referenceKrammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3eng
hcfmusp.relation.referenceKweon OJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240395eng
hcfmusp.relation.referenceLai L, 2007, VIROLOGY, V369, P153, DOI 10.1016/j.virol.2007.07.017eng
hcfmusp.relation.referenceLazzarotto T, 2000, VIRAL IMMUNOL, V13, P137, DOI 10.1089/vim.2000.13.137eng
hcfmusp.relation.referenceLiu XM, 2020, EMERG MICROBES INFEC, V9, P1269, DOI 10.1080/22221751.2020.1773324eng
hcfmusp.relation.referenceLong QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6eng
hcfmusp.relation.referenceLong QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1eng
hcfmusp.relation.referenceMARTIN KA, 1994, J INFECT DIS, V170, P991, DOI 10.1093/infdis/170.4.991eng
hcfmusp.relation.referenceMazzini L, 2021, J IMMUNOL METHODS, V489, DOI 10.1016/j.jim.2020.112937eng
hcfmusp.relation.referenceMenezes P. D. L., 2020, BRAZIL IS PROJECTED, DOI [10.1101/2020.04.28.20083675, DOI 10.1101/2020.04.28.20083675]eng
hcfmusp.relation.referenceMiot Hélio Amante, 2017, J. vasc. bras., V16, P88, DOI 10.1590/1677-5449.041117eng
hcfmusp.relation.referenceNagao-Dias AT, 2007, BRAZ J INFECT DIS, V11, P215, DOI 10.1590/S1413-86702007000200009eng
hcfmusp.relation.referenceOMS, 2020, WHO COVID 19 WEEKL E, V1, P4eng
hcfmusp.relation.referencePadoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443eng
hcfmusp.relation.referencePegu P, 2013, J VIROL, V87, P1708, DOI 10.1128/JVI.02544-12eng
hcfmusp.relation.referenceNguyen-Contant P, 2020, MBIO, V11, DOI 10.1128/mBio.01991-20eng
hcfmusp.relation.referencePoland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1eng
hcfmusp.relation.referencePULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1eng
hcfmusp.relation.referencePuschnik A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002274eng
hcfmusp.relation.referenceRai P, 2021, APPL MICROBIOL BIOT, V105, P441, DOI 10.1007/s00253-020-11061-5eng
hcfmusp.relation.referenceRebello CJ, 2020, INT J OBESITY, V44, P1810, DOI 10.1038/s41366-020-0640-5eng
hcfmusp.relation.referenceRibas RM, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101675eng
hcfmusp.relation.referenceSantana SS, 2012, IMMUNOL LETT, V143, P193, DOI 10.1016/j.imlet.2012.02.008eng
hcfmusp.relation.referenceSatoguina JS, 2005, J IMMUNOL, V174, P4718, DOI 10.4049/jimmunol.174.8.4718eng
hcfmusp.relation.referenceScohy A, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104455eng
hcfmusp.relation.referenceSeo S, 2009, KOREAN J LAB MED, V29, P557, DOI 10.3343/kjlm.2009.29.6.557eng
hcfmusp.relation.referenceShih HI, 2020, BIOMED J, V43, P341, DOI 10.1016/j.bj.2020.05.021eng
hcfmusp.relation.referenceSiracusano G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01049eng
hcfmusp.relation.referenceStadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100eng
hcfmusp.relation.referenceStromer A., 2020, DIAGNOSTIC ACCURACY, V2015eng
hcfmusp.relation.referenceSuthar MS, 2020, CELL REP MED, V1, DOI [10.1016/j.xcrm.2020.100040, 10.1101/2020.05.03.20084442]eng
hcfmusp.relation.referenceTai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4eng
hcfmusp.relation.referenceValdivia A, 2021, J MED VIROL, V93, P1141, DOI 10.1002/jmv.26344eng
hcfmusp.relation.referenceWalls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]eng
hcfmusp.relation.referenceWalsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906eng
hcfmusp.relation.referenceWang P, 2020, J VIROL METHODS, V283, DOI 10.1016/j.jviromet.2020.113919eng
hcfmusp.relation.referenceWard S, 2020, J ALLERGY CLIN IMMUN, V146, P23, DOI 10.1016/j.jaci.2020.05.012eng
hcfmusp.relation.referenceWolf J, 2020, CLIN CHIM ACTA, V511, P352, DOI 10.1016/j.cca.2020.10.035eng
hcfmusp.relation.referenceWolfel R, 2020, NATURE, V588, pE35, DOI [10.1159/000505601, 10.1038/s41586-020-2984-3, 10.1038/s41586-020-2196-x]eng
hcfmusp.relation.referenceWorld Health Organization, 2020, LAB BIOS GUID REL COeng
hcfmusp.relation.referenceYang HS, 2020, CLIN CHIM ACTA, V509, P117, DOI 10.1016/j.cca.2020.06.004eng
hcfmusp.relation.referenceZhang JJ, 2021, ALLERGY, V76, P533, DOI [10.1111/all.14238, 10.1111/all.14496]eng
hcfmusp.relation.referenceZhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4eng
hcfmusp.relation.referenceZhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344eng
hcfmusp.relation.referenceZheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication1c8fa285-4408-4b15-9ed4-a7209ef85fc5
relation.isAuthorOfPublication.latestForDiscovery1c8fa285-4408-4b15-9ed4-a7209ef85fc5
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_MOURA_Assessment_of_avidity_related_to_IgG_subclasses_in_2021.PDF
Tamanho:
1.49 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/49
Artigos e Materiais de Revistas Científicas - ODS/03